Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial
Crossref DOI link: https://doi.org/10.1007/s11239-016-1354-3
Published Online: 2016-03-14
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Werth, Sebastian
Bauersachs, Rupert
Gerlach, Horst
Rabe, Eberhard
Schellong, Sebastian
Beyer-Westendorf, Jan
Funding for this research was provided by:
Bayer HealthCare
Text and Data Mining valid from 2016-03-14